Author

S. A. Bender

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

A. Tsherniak· 2 shared C. C. Mader· 2 shared J. A. Roth· 2 shared J. M. McFarland· 2 shared A. A. Tang· 1 shared A. C. Greenwald· 1 shared A. Plotnikov· 1 shared A. Regev· 1 shared

Activity by Year

2019-2019 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Tsherniak

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Pan-cancer single cell RNA-seq uncovers recurring programs of cellular heterogeneity

G. S. Kinker, A. C. Greenwald, R. Tal, Z. Orlova, M. S. Cuoco, J. M. McFarland, A. Warren, C. Rodman, J. A. Roth, S. A. Bender, B. Kumar, J. W. Rocco, P. A. Fernandes, C. C. Mader, H. Keren-Shaul, , I. Tirosh

The paper uses single-cell RNA-seq to analyze cancer cell lines and identifies recurring expression programs of heterogeneity that mirror those in tumors, suggesting intrinsic plasticity contributes to intra-tumoral diversity.

bioRxiv · Oct 21, 2019 · PreprintCancer Biology

Non-oncology drugs are a source of previously unappreciated anti-cancer activity

S. M. Corsello, R. T. Nagari, R. D. Spangler, J. Rossen, M. Kocak, J. G. Bryan, R. Humeidi, D. Peck, X. Wu, A. A. Tang, V. M. Wang, S. A. Bender, E. Lemire, R. Narayan, P. Montgomery, , T. R. Golub

The paper identifies non-oncology drugs with anti-cancer activity across 578 cancer cell lines using PRISM, finding that many drugs selectively inhibit cancer cells based on molecular features.

bioRxiv · Aug 9, 2019Cancer Biology